Dr. Paik on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC
May 9th 2018Paul K. Paik, MD, clinical director of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of lorlatinib may alter the landscape for patients with ALK-positive non–small cell lung cancer (NSCLC).
Read More